Proposed Regulatory Reforms to Mandate Quality Audits for Blood Centres
Proposed regulatory changes would mandate external quality audits for blood centres, imposing testing suspensions and fines on facilities that fail to meet…

Regulatory authorities are considering amendments to the Drugs Rules, 1945, that would make participation in External Quality Assessment Schemes (EQAS) legally binding for approximately 5,000 registered blood centres. Currently, participation in these proficiency tests is voluntary, leaving significant gaps in oversight and accountability for testing inaccuracies.
The proposed framework mandates that blood centres undergo periodic proficiency testing for blood grouping, cross-matching, and infectious disease screening, including HIV, Hepatitis B, Hepatitis C, syphilis, and malaria. Under the new guidelines, facilities that fail to meet proficiency standards would be prohibited from conducting routine testing until they complete a formal root cause analysis and implement corrective and preventive action protocols.
Enforcement of these standards would involve state drug controllers, who would receive direct access to audit reports to ensure compliance. Potential penalties for non-compliant facilities include statutory fines, the suspension of testing privileges, and further disciplinary action. This shift aims to align domestic transfusion safety systems with international standards, such as those observed in the US, UK, and EU, where laboratory accreditation is directly linked to external quality performance.
Drugs Rules
The initiative follows reports of medical incidents involving infected or mismatched blood transfusions, which have highlighted systemic vulnerabilities in the current quality management infrastructure. In 2024-25, India collected 14.6 million units of blood, with approximately 70% sourced from voluntary donors. The high volume of supply necessitates a more rigorous, centralized monitoring system to mitigate risks to patient safety.
The proposal is currently under review by the Drugs Consultative Committee, a statutory advisory panel. If approved, Blood Transfusion Council will oversee a phased transition plan to integrate these requirements without disrupting blood supply. The government intends to establish standardized pricing for these tests, using existing models as a benchmark for operational costs.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- GSK wins FDA approval for Nelkarmi after 49% response rate
- Europe faces 35,000 drug-resistance deaths a year
- Ebola vaccine trial starts as Congo outbreak widens again
- Alzheimer’s blood test flags future symptom risk in study
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

